CA2701534C - Intermediates and methods for the synthesis of halichondrin b analogs - Google Patents
Intermediates and methods for the synthesis of halichondrin b analogs Download PDFInfo
- Publication number
- CA2701534C CA2701534C CA2701534A CA2701534A CA2701534C CA 2701534 C CA2701534 C CA 2701534C CA 2701534 A CA2701534 A CA 2701534A CA 2701534 A CA2701534 A CA 2701534A CA 2701534 C CA2701534 C CA 2701534C
- Authority
- CA
- Canada
- Prior art keywords
- compound
- alkyl
- formula
- protecting group
- cyclic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/28—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
- C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Furan Compounds (AREA)
- Silicates, Zeolites, And Molecular Sieves (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99762507P | 2007-10-03 | 2007-10-03 | |
| US60/997,625 | 2007-10-03 | ||
| PCT/US2008/078762 WO2009046308A1 (en) | 2007-10-03 | 2008-10-03 | Intermediates and methods for the synthesis of halichondrin b analogs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2701534A1 CA2701534A1 (en) | 2009-04-09 |
| CA2701534C true CA2701534C (en) | 2017-02-21 |
Family
ID=40019255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2701534A Active CA2701534C (en) | 2007-10-03 | 2008-10-03 | Intermediates and methods for the synthesis of halichondrin b analogs |
Country Status (11)
| Country | Link |
|---|---|
| US (6) | US8093410B2 (enExample) |
| EP (2) | EP2578576B9 (enExample) |
| JP (1) | JP5735277B2 (enExample) |
| CN (3) | CN104311571B (enExample) |
| BR (1) | BRPI0817909B1 (enExample) |
| CA (1) | CA2701534C (enExample) |
| IL (1) | IL204791A (enExample) |
| MX (1) | MX2010003599A (enExample) |
| RU (1) | RU2489437C2 (enExample) |
| SG (1) | SG10201811715YA (enExample) |
| WO (1) | WO2009046308A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2682878B2 (ja) | 1989-11-27 | 1997-11-26 | 上村工業株式会社 | シールド付き電気めっき装置 |
| CA2632433C (en) * | 1998-06-17 | 2012-02-07 | Eisai R & D Management Co., Ltd. | Methods for preparing macrocyclic analogs and intermediates for preparing same |
| KR101434673B1 (ko) | 2004-06-03 | 2014-08-26 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 할리콘드린 ｂ 유사체의 제조를 위한 중간체 |
| EP2578576B9 (en) * | 2007-10-03 | 2016-09-14 | Eisai R&D Management Co., Ltd. | Intermediates for the synthesis of halichondrin B analogs |
| RU2517167C2 (ru) * | 2008-04-04 | 2014-05-27 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Аналоги галихондрина в |
| DE102009012660A1 (de) * | 2009-03-13 | 2010-09-16 | H.C. Starck Clevios Gmbh | Polymerbeschichtungen mit verbesserter Temperaturstabilität |
| PE20120923A1 (es) | 2009-03-30 | 2012-08-27 | Eisai Randd Man Co Ltd | Composiciones farmaceuticas comprendiendo liposomas que contiene eribulina o una sal del mismo |
| US8203010B2 (en) | 2010-01-26 | 2012-06-19 | Eisai R&D Management Co., Ltd. | Compounds useful in the synthesis of halichondrin B analogs |
| CN102225921B (zh) * | 2011-04-26 | 2013-04-24 | 中国人民解放军第二军医大学 | 一种环戊烷聚酮类化合物simplextone A及其用途 |
| WO2012147900A1 (en) | 2011-04-28 | 2012-11-01 | Eisai R&D Management Co., Ltd. | Microreactor process for halichondrin b analog synthesis |
| AU2013353745A1 (en) | 2012-12-04 | 2015-06-11 | Eisai R&D Management Co., Ltd. | Use of eribulin in the treatment of breast cancer |
| CN105338977B (zh) | 2013-06-26 | 2018-10-16 | 卫材R&D管理有限公司 | 艾日布林和乐伐替尼作为治疗癌症的联合疗法的用途 |
| CA2929084C (en) | 2013-11-04 | 2022-01-11 | Eisai R&D Management Co., Ltd. | Macrocyclization reactions and intermediates and other fragments useful in the synthesis of analogs of halichondrin b |
| BR112016012237B1 (pt) | 2013-12-06 | 2023-02-07 | Eisai R&D Management Co., Ltd | Métodos úteis na síntese de análogos de halicondrina b |
| WO2015183961A1 (en) | 2014-05-28 | 2015-12-03 | Eisai R&D Management Co., Ltd | Use of eribulin in the treatment of cancer |
| WO2016003975A1 (en) | 2014-06-30 | 2016-01-07 | President And Fellows Of Harvard College | Synthesis of halichondrin analogs and uses thereof |
| US10208058B2 (en) | 2014-09-09 | 2019-02-19 | Cipla Limited | Process for the preparation of macrocyclic ketone analogs of halichondrin B or pharmaceutically acceptable salts and intermediates thereof |
| KR20240064733A (ko) | 2015-03-04 | 2024-05-13 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| MX386547B (es) | 2015-03-04 | 2025-03-19 | Merck Sharp & Dohme | Combinación de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cáncer. |
| WO2016176560A1 (en) | 2015-04-30 | 2016-11-03 | President And Fellows Of Harvard College | Chromium-mediated coupling and application to the synthesis of halichondrins |
| MX392296B (es) | 2015-05-07 | 2025-03-24 | Eisai R&D Man Co Ltd | Reacciones de macrociclizacion e intermediarios y otros fragmentos utiles en la sintesis de macrolidos de halicondrina. |
| MX377663B (es) | 2016-02-12 | 2025-03-11 | Eisai R&D Man Co Ltd | Intermediarios en la sintesis de eribulina y metodos de sintesis relacionados. |
| MY199595A (en) | 2016-03-02 | 2023-11-08 | Eisai R&D Man Co Ltd | Eribulin-based antibody-drug conjugates and methods of use |
| WO2017188350A1 (ja) | 2016-04-28 | 2017-11-02 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍の成長を抑制する方法 |
| US11136335B2 (en) * | 2016-06-30 | 2021-10-05 | Eisai R&D Management Co., Ltd. | Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof |
| SG11201902974PA (en) | 2016-10-14 | 2019-05-30 | Merck Sharp & Dohme | Combination of a pd-1 antagonist and eribulin for treating urothelial cancer |
| JP6978758B2 (ja) | 2016-11-11 | 2021-12-08 | プレジデント アンド フェローズ オブ ハーバード カレッジ | パラジウム媒介ケトール化 |
| US9938288B1 (en) | 2017-04-05 | 2018-04-10 | President And Fellows Of Harvard College | Macrocyclic compound and uses thereof |
| SI3606928T1 (sl) | 2017-04-05 | 2023-02-28 | President And Fellows Of Harvard College | Makrociklična spojina in njene uporabe |
| HUE061306T2 (hu) * | 2017-07-06 | 2023-06-28 | Harvard College | Halikondrinok szintézise |
| US11498892B2 (en) | 2017-07-06 | 2022-11-15 | President And Fellows Of Harvard College | Fe/Cu-mediated ketone synthesis |
| US20190046513A1 (en) | 2017-08-10 | 2019-02-14 | Huya Bioscience International, Llc | Combination therapies of hdac inhibitors and tubulin inhibitors |
| CN111566113B (zh) | 2017-11-15 | 2024-01-09 | 哈佛大学的校长及成员们 | 大环化合物及其用途 |
| EP3713565A1 (en) | 2017-11-20 | 2020-09-30 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
| MX2020006945A (es) | 2018-01-03 | 2020-11-09 | Eisai R&D Man Co Ltd | Reaccion de prins y compuestos utiles en la sintesis de macrolidos de halicondrina y analogos de los mismos. |
| US11447499B2 (en) | 2019-06-14 | 2022-09-20 | Rk Pharma Inc. | Process for the preparation of eribulin mesylate intermediate |
| US12247239B2 (en) | 2019-06-21 | 2025-03-11 | Council Of Scientific & Industrial Research | Chemo-enzymatic process for the preparation of homopropargylic alcohol |
| ES3075649T3 (en) | 2019-07-26 | 2026-08-06 | Eisai R&D Man Co Ltd | Pharmaceutical composition for treating tumor |
| US11083705B2 (en) | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| CN110981903A (zh) * | 2019-11-28 | 2020-04-10 | 南京正济医药研究有限公司 | 一种艾日布林中间体化合物提高光学纯度的精制方法 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2027890C3 (de) * | 1970-06-06 | 1979-02-01 | Kali Chemie Ag | 8-AIkoxy oder -Benzyloxy-3-methyl-lO- methylen-2,9-dioxatricyclo-(43,l,03,7 )-decan-4-one und 8-AIkoxy oder 8-Benzyloxy-3,10-dimethyl-2,9dioxatricyclo- (43,1,O" )-decan-4-one |
| SU652180A1 (ru) | 1975-12-16 | 1979-03-15 | Краснодарский политехнический институт | 1(Фурил-2,)-2-(2-,, формилфурил-5,, ) этилен или его метильное производное как промежуточный продукт дл синтеза фуран-2,5-дикарбоновой кислоты и способ его получени |
| US4086245A (en) * | 1976-12-09 | 1978-04-25 | The Upjohn Company | Antibiotics 7-O-alkylnogarols |
| SU722912A1 (ru) * | 1978-03-06 | 1980-03-25 | Уфимский Нефтяной Институт | Способ получени 5-метил/-4оксо3,6,8-триоксабицикло/ (3,2,1)-октана |
| US5436238A (en) * | 1992-03-12 | 1995-07-25 | President And Fellows Of Harvard College | Halichondrins and related compounds |
| US5338865A (en) * | 1992-03-12 | 1994-08-16 | President And Fellows Of Harvard College | Synthesis of halichondrin B and norhalichondrin B |
| GB9206244D0 (en) * | 1992-03-23 | 1992-05-06 | Pharma Mar Sa | Cytotoxic compound from a marine sponge |
| TW255880B (enExample) | 1992-09-09 | 1995-09-01 | Hoechst Ag | |
| WO1998009942A1 (en) | 1996-09-06 | 1998-03-12 | Eli Lilly And Company | Catalytic selective sulfonylation process |
| US6870058B2 (en) | 1996-12-03 | 2005-03-22 | The Trustees Of The University Of Pennsylvania | Compounds which mimic the chemical and biological properties of discodermolide |
| US8097648B2 (en) | 1998-06-17 | 2012-01-17 | Eisai R&D Management Co., Ltd. | Methods and compositions for use in treating cancer |
| US6653341B1 (en) * | 1998-06-17 | 2003-11-25 | Eisai Co., Ltd. | Methods and compositions for use in treating cancer |
| CA2632433C (en) * | 1998-06-17 | 2012-02-07 | Eisai R & D Management Co., Ltd. | Methods for preparing macrocyclic analogs and intermediates for preparing same |
| DE10106647A1 (de) | 2001-02-12 | 2002-08-22 | Univ Hannover | Ratjadon-Derivate zum Hemmen des Zellwachstums |
| CN108997267A (zh) * | 2004-06-03 | 2018-12-14 | 卫材R&D管理有限公司 | 用于制备软海绵素b的类似物的中间体 |
| KR101434673B1 (ko) | 2004-06-03 | 2014-08-26 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 할리콘드린 ｂ 유사체의 제조를 위한 중간체 |
| US20060045846A1 (en) | 2004-08-30 | 2006-03-02 | Horstmann Thomas E | Reagents and methods for labeling terminal olefins |
| JP2008522623A (ja) | 2004-12-09 | 2008-07-03 | エーザイ株式会社 | ハリコンドリンｂアナログを使用した癌治療でのチューブリンアイソタイプのスクリーニング |
| EP1940758B1 (en) | 2005-09-26 | 2012-11-28 | Symrise AG | Intramolecular prins reaction |
| WO2008010776A1 (en) | 2006-07-21 | 2008-01-24 | Agency For Science, Technology And Research | Aigialomycin d and derivatives thereof and their use in treating cancer or malaria or a microbial infection |
| JPWO2009014105A1 (ja) | 2007-07-20 | 2010-10-07 | 株式会社山田養蜂場本社 | 新規カルボン酸およびそれを有効成分とする抗うつ用組成物 |
| EP2578576B9 (en) * | 2007-10-03 | 2016-09-14 | Eisai R&D Management Co., Ltd. | Intermediates for the synthesis of halichondrin B analogs |
| CN101910180A (zh) * | 2007-11-16 | 2010-12-08 | 卫材R&D管理有限公司 | 用于软海绵素b类似物合成的新颖中间体和用于该中间体的新颖脱磺酰化反应 |
| RU2517167C2 (ru) * | 2008-04-04 | 2014-05-27 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Аналоги галихондрина в |
| JP5371091B2 (ja) | 2009-01-23 | 2013-12-18 | 三菱レイヨン株式会社 | モノスルホン酸エステルの製造方法 |
| US8203010B2 (en) | 2010-01-26 | 2012-06-19 | Eisai R&D Management Co., Ltd. | Compounds useful in the synthesis of halichondrin B analogs |
| WO2012147900A1 (en) | 2011-04-28 | 2012-11-01 | Eisai R&D Management Co., Ltd. | Microreactor process for halichondrin b analog synthesis |
| CA2857385A1 (en) | 2011-11-30 | 2013-06-06 | Alphora Research Inc. | Process for preparation of (3r)-2,4-di-leaving group-3-methylbut-1-ene |
| CN104334562A (zh) | 2012-03-30 | 2015-02-04 | 阿方拉研究股份有限公司 | 用于制备软海绵素b的大环c1-酮类似物的合成方法及其中有用的中间体 |
| WO2015000070A1 (en) | 2013-07-03 | 2015-01-08 | Alphora Research Inc. | Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein including intermediates containing -so2-(p-tolyl) groups |
| CA2929084C (en) | 2013-11-04 | 2022-01-11 | Eisai R&D Management Co., Ltd. | Macrocyclization reactions and intermediates and other fragments useful in the synthesis of analogs of halichondrin b |
| BR112016012237B1 (pt) | 2013-12-06 | 2023-02-07 | Eisai R&D Management Co., Ltd | Métodos úteis na síntese de análogos de halicondrina b |
| US10208058B2 (en) | 2014-09-09 | 2019-02-19 | Cipla Limited | Process for the preparation of macrocyclic ketone analogs of halichondrin B or pharmaceutically acceptable salts and intermediates thereof |
| MX392296B (es) | 2015-05-07 | 2025-03-24 | Eisai R&D Man Co Ltd | Reacciones de macrociclizacion e intermediarios y otros fragmentos utiles en la sintesis de macrolidos de halicondrina. |
| MX377663B (es) | 2016-02-12 | 2025-03-11 | Eisai R&D Man Co Ltd | Intermediarios en la sintesis de eribulina y metodos de sintesis relacionados. |
| US11136335B2 (en) | 2016-06-30 | 2021-10-05 | Eisai R&D Management Co., Ltd. | Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof |
| WO2018217894A1 (en) | 2017-05-24 | 2018-11-29 | Eisai R&D Management Co., Ltd. | Fluorine-labelled halichondrin derivatives and related methods of synthesis |
| MX2020006945A (es) | 2018-01-03 | 2020-11-09 | Eisai R&D Man Co Ltd | Reaccion de prins y compuestos utiles en la sintesis de macrolidos de halicondrina y analogos de los mismos. |
-
2008
- 2008-10-03 EP EP12191294.3A patent/EP2578576B9/en active Active
- 2008-10-03 SG SG10201811715YA patent/SG10201811715YA/en unknown
- 2008-10-03 JP JP2010528165A patent/JP5735277B2/ja active Active
- 2008-10-03 CN CN201410421907.5A patent/CN104311571B/zh active Active
- 2008-10-03 CN CN200880119686.9A patent/CN101883763B/zh active Active
- 2008-10-03 RU RU2010117520/04A patent/RU2489437C2/ru active
- 2008-10-03 BR BRPI0817909-3A patent/BRPI0817909B1/pt active IP Right Grant
- 2008-10-03 EP EP08836425.2A patent/EP2200992B1/en active Active
- 2008-10-03 US US12/245,149 patent/US8093410B2/en active Active
- 2008-10-03 CN CN201810736587.0A patent/CN108948039B/zh active Active
- 2008-10-03 WO PCT/US2008/078762 patent/WO2009046308A1/en not_active Ceased
- 2008-10-03 CA CA2701534A patent/CA2701534C/en active Active
- 2008-10-03 MX MX2010003599A patent/MX2010003599A/es unknown
-
2010
- 2010-03-28 IL IL204791A patent/IL204791A/en active IP Right Grant
-
2011
- 2011-12-22 US US13/334,516 patent/US8987479B2/en active Active
-
2015
- 2015-02-17 US US14/624,033 patent/US9604993B2/en active Active
-
2016
- 2016-04-07 US US15/092,850 patent/US9802953B2/en active Active
-
2017
- 2017-10-18 US US15/787,268 patent/US10214539B2/en active Active
-
2019
- 2019-02-25 US US16/284,405 patent/US10717743B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10717743B2 (en) | Intermediates and methods for the synthesis of halichondrin B analogs | |
| DE69615016T2 (de) | Pentacyclische verbindungen | |
| JP2018522944A (ja) | カンナビジオール及びδ−９−テトラヒドロカンナビノールの生成のためのプロセス | |
| HUP0402140A2 (hu) | Eljárás hexahidrofuro [2,3-b]furán-3-ol előállítására | |
| CN1938316A (zh) | 制备(3R,3aS,6aR)六氢－呋喃并[2,3－b]呋喃－3－醇的方法 | |
| JP7442663B2 (ja) | Ｓｇｌｔ阻害剤の合成に有用な中間体およびこれを用いたｓｇｌｔ阻害剤の製造方法 | |
| WO2020155613A1 (zh) | 一种海鞘素化合物及其中间体的制备方法 | |
| EP1042328A1 (en) | Sarcodictyin and eleutherobin derivatives useful for stabilising microtubles | |
| CA2902009A1 (en) | Isohexide monotriflates and process for synthesis thereof | |
| AU2011271489A1 (en) | Preparation of tesetaxel and related compounds and corresponding synthesis intermediate | |
| Fernández et al. | Stereocontrolled transformation of nitrohexofuranoses into cyclopentylamines via 2-oxabicyclo [2.2. 1] heptanes. IV: Synthesis of enantiopure methyl (1S, 2R, 3R, 4R, 5S)-5-benzyloxycarbonylamino-2, 3-isopropylidenedioxy-4-methoxycyclopentanecarboxylate | |
| TANAKA et al. | Synthetic Studies on a Picrotoxane Sesquiterpene, Coriamyrtin. I. The Grignard Reaction of 5-(2-Methyl-1, 3-dioxo-2-cyclopentyl) methyl-2, 5H-furanone with Isopropenylmagnesium Bromide and Stereochemistries of the Products | |
| Pimpalpalle et al. | Lewis acid-catalyzed stereoselective lactonization and subsequent glycosidation of 2-C-malonyl carbohydrates | |
| JP2000229961A (ja) | ヒドロナフト［２，３−ｃ］フラン誘導体およびその製造方法 | |
| WO2001047906A1 (en) | Process for the production of 5-oxy-7-oxabicyclo-[4.1.0]hept-3-e ne-3-carboxylic acid esters | |
| Horneman et al. | Highly Functionalised Cyclopentanes by Radical Cyclisation of Unsaturated Bromolactones III. Preparation of Carbaaldohexofuranoses. Determination of the Relative Configuration at C-4/C-5 of 2, 3-Unsaturated Heptono-1, 4-lactones by Means of 1H NMR Spectroscopy | |
| WO2023276983A1 (ja) | ベラプロストまたは光学活性体の合成中間体およびその製造方法 | |
| WO2012075122A2 (en) | Processes and intermediates for preparing substituted hexahydrofuro [2,3-b] furans | |
| JPS60197662A (ja) | カ−バメ−ト及びその製法 | |
| JPWO1996033998A1 (ja) | 五環性化合物 | |
| KOJIMA et al. | Synthesis of 3-Oxa-5-alkylideneisocarbacyclins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20130927 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD Year of fee payment: 16 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240927 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240927 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240927 |
|
| H13 | Ip right lapsed |
Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE Effective date: 20260519 |